Jesper Lau, Ph.D.

Vice President, Chemical Biology at Novo Nordisk A/S

Agenda Sessions

• KEYNOTE PRESENTATION: Discovery and Development of Semaglutide – The First Orally Available GLP-1 Peptide for Treatment of Type 2 Diabetes

  10:30am

  View Session

• LIVE Keynote Q&A Including Audience Interaction: Attendees Please Bring Your Questions to This Session

  11:00am

  View Session

• SESSION NAME: Cutting-Edge Technologies for Peptide Discovery - SESSION CHAIR & SPEAKERS BELOW

  On Demand

  View Session

Speakers at this event